Sakurauchi, Y., Matsumoto, Y., Shinzato, T., Takai, I., Nakamura, Y., Sato, M., Nakai, S., Miwa, M., Morita, H., Miwa, T., Amano, I., and Maeda, K
Food and Drug Administration (FDA) approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related condition, such as high blood pressure or type 2 diabetes
ACA Section 1557 Nondiscrimination: Section 1557 of the ACA prohibits covered entities from discriminating in certain health programs and activities based on disability, which is defined as a physical or mental impairment that substantially limits one or more major life activities as evidenced by a permanent or substantial impairment
For more insight into how our research team vets, qualifies, and ranks providers, review our full methodology here
PlexusDx providers screen all patients for thyroid cancer risk and offer tirzepatide injections or oral formulations as alternatives, since tirzepatide targets a different peptide pathway (GIP and GLP-1 combined) without the same thyroid-specific concerns
